ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 13.6% on Friday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 4.09 ($0.05). Approximately 21,797,100 shares were traded during trading, an increase of 14% from the average daily volume of 19,107,500 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Stock Up 11.1 %
The business has a 50-day moving average price of GBX 1.71 and a 200-day moving average price of GBX 1.72. The firm has a market capitalization of £16.65 million, a P/E ratio of -399.90 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Why Invest in High-Yield Dividend Stocks?
- Abbott Laboratories Will Outperform Healthcare Stocks in 2025
- What is a buyback in stocks? A comprehensive guide for investors
- PepsiCo: 53 Years of Dividend Growth and Still Going Strong
- What is a SEC Filing?
- Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
